postcomposition_id	descriptor_id	assertion_id	disorder_id	disorder_name	source_file	section	section_index	section_name	section_description	descriptor_path	descriptor_preferred_term	descriptor_term_id	descriptor_term_label	relation_type	relation_index	relation_path	predicate_preferred_term	predicate_term_id	predicate_term_label	value_preferred_term	value_term_id	value_term_label	value_literal	raw_json
12	62	56	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	0	All-Trans Retinoic Acid (ATRA)	Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			all-trans-retinoic acid	CHEBI:15367	all-trans-retinoic acid		"{""preferred_term"": ""all-trans-retinoic acid"", ""term"": {""id"": ""CHEBI:15367"", ""label"": ""all-trans-retinoic acid""}}"
13	64	57	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	1	Arsenic Trioxide (ATO)	ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			arsenic trioxide	CHEBI:30621	diarsenic trioxide		"{""preferred_term"": ""arsenic trioxide"", ""term"": {""id"": ""CHEBI:30621"", ""label"": ""diarsenic trioxide""}}"
15	195	186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	treatment_term	retinoid agent therapy	MAXO:0000237	retinoid agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	retinoid	NCIT:C68299	Retinoid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""retinoid"", ""term"": {""id"": ""NCIT:C68299"", ""label"": ""Retinoid""}}}"
16	198	187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	treatment_term	retinoid agent therapy	MAXO:0000237	retinoid agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	trifarotene	NCIT:C118577	Trifarotene		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""trifarotene"", ""term"": {""id"": ""NCIT:C118577"", ""label"": ""Trifarotene""}}}"
17	201	188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	treatment_term	antimicrobial agent therapy	MAXO:0001021	antimicrobial agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	benzoyl peroxide	NCIT:C47411	Benzoyl Peroxide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}"
18	204	189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	treatment_term	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	antibiotic	NCIT:C258	Antibiotic		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""antibiotic"", ""term"": {""id"": ""NCIT:C258"", ""label"": ""Antibiotic""}}}"
19	207	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	clindamycin phosphate	NCIT:C47978	Clindamycin Phosphate		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""clindamycin phosphate"", ""term"": {""id"": ""NCIT:C47978"", ""label"": ""Clindamycin Phosphate""}}}"
20	207	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	adapalene	NCIT:C28989	Adapalene		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adapalene"", ""term"": {""id"": ""NCIT:C28989"", ""label"": ""Adapalene""}}}"
21	207	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	2	treatment_term.qualifiers[2]	therapeutic agent	NCIT:C2259	Therapeutic Agent	benzoyl peroxide	NCIT:C47411	Benzoyl Peroxide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}"
22	214	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	treatment_term	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	tetracycline antibiotic	NCIT:C1595	Tetracycline Antibiotic		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tetracycline antibiotic"", ""term"": {""id"": ""NCIT:C1595"", ""label"": ""Tetracycline Antibiotic""}}}"
23	217	192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	treatment_term	retinoid agent therapy	MAXO:0000237	retinoid agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	isotretinoin	NCIT:C603	Isotretinoin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""isotretinoin"", ""term"": {""id"": ""NCIT:C603"", ""label"": ""Isotretinoin""}}}"
24	220	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term	hormone modifying therapy	MAXO:0000283	hormone modifying therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	oral contraceptive	NCIT:C389	Oral Contraceptive		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""oral contraceptive"", ""term"": {""id"": ""NCIT:C389"", ""label"": ""Oral Contraceptive""}}}"
25	220	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term	hormone modifying therapy	MAXO:0000283	hormone modifying therapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	spironolactone	NCIT:C840	Spironolactone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}"
26	225	194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	chemical peel	NCIT:C93203	Chemical Peel		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}"
27	228	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	chemical peel	NCIT:C93203	Chemical Peel		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}"
28	228	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	azelaic acid	NCIT:C47407	Azelaic Acid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azelaic acid"", ""term"": {""id"": ""NCIT:C47407"", ""label"": ""Azelaic Acid""}}}"
29	233	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	chemical peel	NCIT:C93203	Chemical Peel		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}"
30	233	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	glycolic acid	NCIT:C83737	Glycolic Acid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""glycolic acid"", ""term"": {""id"": ""NCIT:C83737"", ""label"": ""Glycolic Acid""}}}"
31	233	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	2	treatment_term.qualifiers[2]	therapeutic agent	NCIT:C2259	Therapeutic Agent	topical trichloroacetic acid	NCIT:C125002	Topical Trichloroacetic Acid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical trichloroacetic acid"", ""term"": {""id"": ""NCIT:C125002"", ""label"": ""Topical Trichloroacetic Acid""}}}"
32	240	197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	laser therapy	NCIT:C15466	Laser Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}"
33	243	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	vitamin C	NCIT:C68507	Vitamin C		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vitamin C"", ""term"": {""id"": ""NCIT:C68507"", ""label"": ""Vitamin C""}}}"
34	243	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	topical vitamin E	NCIT:C67081	Topical Vitamin E		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical vitamin E"", ""term"": {""id"": ""NCIT:C67081"", ""label"": ""Topical Vitamin E""}}}"
35	248	199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	phototherapy	NCIT:C15301	Phototherapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}"
36	251	200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	phototherapy	NCIT:C15301	Phototherapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}"
37	254	201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	photodynamic therapy	NCIT:C15300	Photodynamic Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""photodynamic therapy"", ""term"": {""id"": ""NCIT:C15300"", ""label"": ""Photodynamic Therapy""}}}"
38	257	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	laser therapy	NCIT:C15466	Laser Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}"
39	257	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	platelet-rich plasma	NCIT:C106557	Platelet-rich Plasma		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""platelet-rich plasma"", ""term"": {""id"": ""NCIT:C106557"", ""label"": ""Platelet-rich Plasma""}}}"
40	262	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	laser therapy	NCIT:C15466	Laser Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}"
41	262	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	1	treatment_term.qualifiers[1]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	infrared laser therapy	NCIT:C66918	Infrared Laser Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""infrared laser therapy"", ""term"": {""id"": ""NCIT:C66918"", ""label"": ""Infrared Laser Therapy""}}}"
61	387	330	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	3	Systemic Therapy	Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			sorafenib	CHEBI:50924	sorafenib		"{""preferred_term"": ""sorafenib"", ""term"": {""id"": ""CHEBI:50924"", ""label"": ""sorafenib""}}"
63	409	376	14	Ainhum	Ainhum.yaml	treatments	0	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	excision	NCIT:C15232	Excision		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}"
64	438	400	15	Akinetopsia	Akinetopsia.yaml	treatments	1	Carbamazepine for seizure-related akinetopsia	Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			carbamazepine	CHEBI:3387	carbamazepine		"{""preferred_term"": ""carbamazepine"", ""term"": {""id"": ""CHEBI:3387"", ""label"": ""carbamazepine""}}"
81	565	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
82	565	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"
83	565	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
94	868	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			dabrafenib	CHEBI:75045	dabrafenib		"{""preferred_term"": ""dabrafenib"", ""term"": {""id"": ""CHEBI:75045"", ""label"": ""dabrafenib""}}"
95	868	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			trametinib	CHEBI:75998	trametinib		"{""preferred_term"": ""trametinib"", ""term"": {""id"": ""CHEBI:75998"", ""label"": ""trametinib""}}"
96	871	844	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	3	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"
113	928	909	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	0	Olaparib	PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			olaparib	CHEBI:83766	olaparib		"{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}"
114	930	910	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	1	Rucaparib	PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			rucaparib	CHEBI:134689	rucaparib		"{""preferred_term"": ""rucaparib"", ""term"": {""id"": ""CHEBI:134689"", ""label"": ""rucaparib""}}"
115	991	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	broad spectrum antibiotic	NCIT:C2883	Broad Spectrum Antibiotic		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}"
116	994	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	anti-infective agent	NCIT:C28254	Anti-Infective Agent		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anti-infective agent"", ""term"": {""id"": ""NCIT:C28254"", ""label"": ""Anti-Infective Agent""}}}"
117	997	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	dexamethasone	NCIT:C620	Dexamethasone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dexamethasone"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Dexamethasone""}}}"
118	1000	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term	supportive care	MAXO:0000950	supportive care	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	fluid therapy	NCIT:C15693	Fluid Replacement Therapy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""fluid therapy"", ""term"": {""id"": ""NCIT:C15693"", ""label"": ""Fluid Replacement Therapy""}}}"
119	1000	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term	supportive care	MAXO:0000950	supportive care	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	anticonvulsant agent	NCIT:C614	Anticonvulsant Agent		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anticonvulsant agent"", ""term"": {""id"": ""NCIT:C614"", ""label"": ""Anticonvulsant Agent""}}}"
120	1005	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	treatment_term	vaccination	MAXO:0001017	vaccination	qualifier	0	treatment_term.qualifiers[0]	immunologic factor	NCIT:C307	Immunologic Factor	vaccine	NCIT:C15260	Vaccine		"{""predicate"": {""preferred_term"": ""immunologic factor"", ""term"": {""id"": ""NCIT:C307"", ""label"": ""Immunologic Factor""}}, ""value"": {""preferred_term"": ""vaccine"", ""term"": {""id"": ""NCIT:C15260"", ""label"": ""Vaccine""}}}"
126	1060	1019	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vismodegib	CHEBI:66903	vismodegib		"{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}"
127	1180	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			prednisone	CHEBI:8382	prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}"
128	1180	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			azathioprine	CHEBI:2948	azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}"
129	1183	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			mycophenolate mofetil	CHEBI:8764	mycophenolate mofetil		"{""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""CHEBI:8764"", ""label"": ""mycophenolate mofetil""}}"
130	1183	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			azathioprine	CHEBI:2948	azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}"
131	1186	1169	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	2	Pirfenidone	Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			pirfenidone	CHEBI:32016	pirfenidone		"{""preferred_term"": ""pirfenidone"", ""term"": {""id"": ""CHEBI:32016"", ""label"": ""pirfenidone""}}"
132	1188	1170	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	3	Nintedanib	Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			nintedanib	CHEBI:85164	nintedanib		"{""preferred_term"": ""nintedanib"", ""term"": {""id"": ""CHEBI:85164"", ""label"": ""nintedanib""}}"
137	1248	1238	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	1	Rituximab	Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			rituximab	CHEBI:64357	rituximab		"{""preferred_term"": ""rituximab"", ""term"": {""id"": ""CHEBI:64357"", ""label"": ""rituximab""}}"
143	1371	1382	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	3	Chemoradiation	Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
147	1475	1541	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	0	Ibrutinib	First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ibrutinib	CHEBI:76612	ibrutinib		"{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}"
148	1477	1542	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			acalabrutinib	CHEBI:167707	acalabrutinib		"{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}"
149	1479	1543	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	2	Venetoclax plus Obinutuzumab	BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"
150	1481	1544	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	3	Chemoimmunotherapy (FCR)	Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cyclophosphamide	CHEBI:4027	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}"
156	1505	1565	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	0	Imatinib	First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
157	1507	1566	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	1	Dasatinib	Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			dasatinib	CHEBI:49375	dasatinib		"{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}"
158	1509	1567	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	2	Nilotinib	Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			nilotinib	CHEBI:52172	nilotinib		"{""preferred_term"": ""nilotinib"", ""term"": {""id"": ""CHEBI:52172"", ""label"": ""nilotinib""}}"
159	1511	1568	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	3	Ponatinib	Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ponatinib	CHEBI:78543	ponatinib		"{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}"
167	1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			sunitinib	CHEBI:38940	sunitinib		"{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}"
168	1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			pazopanib	CHEBI:71219	pazopanib		"{""preferred_term"": ""pazopanib"", ""term"": {""id"": ""CHEBI:71219"", ""label"": ""pazopanib""}}"
169	1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			axitinib	CHEBI:66910	axitinib		"{""preferred_term"": ""axitinib"", ""term"": {""id"": ""CHEBI:66910"", ""label"": ""axitinib""}}"
170	1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			cabozantinib	CHEBI:72317	cabozantinib		"{""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}"
174	1630	1682	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	3	Systemic Therapy	CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
175	1647	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	route of administration	NCIT:C38114	Route of Administration	oral route of administration	NCIT:C38288	Oral Route of Administration		"{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}"
176	1647	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	vancomycin	NCIT:C288	vancomycin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vancomycin"", ""term"": {""id"": ""NCIT:C288"", ""label"": ""vancomycin""}}}"
177	1652	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	route of administration	NCIT:C38114	Route of Administration	oral route of administration	NCIT:C38288	Oral Route of Administration		"{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}"
178	1652	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	fidaxomicin	NCIT:C95509	fidaxomicin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""fidaxomicin"", ""term"": {""id"": ""NCIT:C95509"", ""label"": ""fidaxomicin""}}}"
179	1657	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	treatment_term	fecal microbiota transplantation	MAXO:0000748	fecal microbiota transplantation	qualifier	0	treatment_term.qualifiers[0]	clinical course	NCIT:C28008	Clinical Course	recurrent disease	MONDO:0700096	recurrent disease		"{""predicate"": {""preferred_term"": ""clinical course"", ""term"": {""id"": ""NCIT:C28008"", ""label"": ""Clinical Course""}}, ""value"": {""preferred_term"": ""recurrent disease"", ""term"": {""id"": ""MONDO:0700096"", ""label"": ""recurrent disease""}}}"
180	1660	1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	bezlotoxumab	NCIT:C121379	Bezlotoxumab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bezlotoxumab"", ""term"": {""id"": ""NCIT:C121379"", ""label"": ""Bezlotoxumab""}}}"
181	1689	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term	topical corticosteroid therapy	MAXO:0001553	topical corticosteroid therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	budesonide	NCIT:C66948	Budesonide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""budesonide"", ""term"": {""id"": ""NCIT:C66948"", ""label"": ""Budesonide""}}}"
182	1689	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term	topical corticosteroid therapy	MAXO:0001553	topical corticosteroid therapy	qualifier	1	treatment_term.qualifiers[1]	route of administration	NCIT:C38114	Route of Administration	gastrointestinal route	NCIT:C38295	Gastrointestinal Route of Administration		"{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""gastrointestinal route"", ""term"": {""id"": ""NCIT:C38295"", ""label"": ""Gastrointestinal Route of Administration""}}}"
183	1694	1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	azathioprine	NCIT:C620	Azathioprine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Azathioprine""}}}"
184	1697	1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	infliximab	NCIT:C2894	Infliximab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C2894"", ""label"": ""Infliximab""}}}"
185	1700	1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	tacrolimus	NCIT:C2982	Tacrolimus		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tacrolimus"", ""term"": {""id"": ""NCIT:C2982"", ""label"": ""Tacrolimus""}}}"
186	1704	1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	treatment_term	nutritional supplementation	MAXO:0000106	nutritional supplementation	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	iron supplement	NCIT:C2346	Iron Supplement		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""iron supplement"", ""term"": {""id"": ""NCIT:C2346"", ""label"": ""Iron Supplement""}}}"
193	1932	1997	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	1	Imatinib Targeted Therapy	Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
197	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
198	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
199	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
200	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"
201	1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	4	treatment_term.therapeutic_agent[4]	therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"
205	1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cyclophosphamide	CHEBI:4027	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}"
206	1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
207	1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
208	1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			prednisone	CHEBI:8382	prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}"
225	2220	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
226	2220	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"
227	2220	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
231	2285	2462	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	1	Hydroxyurea	First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"
232	2287	2463	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	2	Anagrelide	Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			anagrelide	CHEBI:142290	anagrelide		"{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}"
236	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vincristine	CHEBI:27375	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}"
237	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
238	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
239	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"
240	2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	4	treatment_term.therapeutic_agent[4]	therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"
253	2375	2565	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	0	Midostaurin	First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			midostaurin	CHEBI:63452	midostaurin		"{""preferred_term"": ""midostaurin"", ""term"": {""id"": ""CHEBI:63452"", ""label"": ""midostaurin""}}"
254	2377	2566	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	1	Gilteritinib	Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			gilteritinib	CHEBI:145372	gilteritinib		"{""preferred_term"": ""gilteritinib"", ""term"": {""id"": ""CHEBI:145372"", ""label"": ""gilteritinib""}}"
269	2832	3015	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	0	Imatinib	First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
270	2834	3016	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	1	Sunitinib	Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			sunitinib	CHEBI:38940	sunitinib		"{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}"
283	2954	3197	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vismodegib	CHEBI:66903	vismodegib		"{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}"
298	3095	3375	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	0	Trastuzumab plus Lapatinib	Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
299	3097	3376	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	1	Trastuzumab plus Pertuzumab	Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
300	3100	3378	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	3	Tucatinib plus Trastuzumab	Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
305	3117	3397	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	0	Trastuzumab plus Chemotherapy	First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
306	3120	3399	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	2	Trastuzumab plus Pembrolizumab plus Chemotherapy	Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"
312	3169	3451	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	1	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired.	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
318	3189	3473	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	0	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
329	3325	3694	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	2	PARP Inhibitors	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			olaparib	CHEBI:83766	olaparib		"{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}"
340	3556	3921	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	0	Ivosidenib	Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ivosidenib	CHEBI:145430	ivosidenib		"{""preferred_term"": ""ivosidenib"", ""term"": {""id"": ""CHEBI:145430"", ""label"": ""ivosidenib""}}"
341	3558	3922	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	1	Enasidenib	Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			enasidenib	CHEBI:145374	enasidenib		"{""preferred_term"": ""enasidenib"", ""term"": {""id"": ""CHEBI:145374"", ""label"": ""enasidenib""}}"
342	3560	3923	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	2	Venetoclax plus Azacitidine	BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"
361	3698	4121	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	0	Imatinib	Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
373	3735	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
374	3735	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			paclitaxel	CHEBI:45863	paclitaxel		"{""preferred_term"": ""paclitaxel"", ""term"": {""id"": ""CHEBI:45863"", ""label"": ""paclitaxel""}}"
381	3915	4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	laser surgery	NCIT:C15268	Laser Surgery		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}"
382	3918	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	laser surgery	NCIT:C15268	Laser Surgery		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}"
383	3918	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term	laser surgical procedure	MAXO:0001578	laser surgical procedure	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	carbon dioxide	NCIT:C65288	Carbon Dioxide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""carbon dioxide"", ""term"": {""id"": ""NCIT:C65288"", ""label"": ""Carbon Dioxide""}}}"
384	3923	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	hyaluronic acid	CHEBI:16336	hyaluronic acid		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""hyaluronic acid"", ""term"": {""id"": ""CHEBI:16336"", ""label"": ""hyaluronic acid""}}}"
385	3926	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	endoscopic procedure	NCIT:C16546	Endoscopic Procedure		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""NCIT:C16546"", ""label"": ""Endoscopic Procedure""}}}"
393	4055	4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	tracheostomy	NCIT:C50458	Tracheostomy		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tracheostomy"", ""term"": {""id"": ""NCIT:C50458"", ""label"": ""Tracheostomy""}}}"
394	4058	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	broad spectrum antibiotic	NCIT:C2883	Broad Spectrum Antibiotic		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}"
395	4061	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	0	treatment_term.qualifiers[0]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	drainage procedure	NCIT:C15286	Drainage Procedure		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""drainage procedure"", ""term"": {""id"": ""NCIT:C15286"", ""label"": ""Drainage Procedure""}}}"
396	4061	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term	surgical procedure	MAXO:0000004	surgical procedure	qualifier	1	treatment_term.qualifiers[1]	therapeutic procedure	NCIT:C49236	Therapeutic Procedure	tooth extraction	NCIT:C5189	Tooth Extraction		"{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tooth extraction"", ""term"": {""id"": ""NCIT:C5189"", ""label"": ""Tooth Extraction""}}}"
407	4176	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	Chemoprevention	Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			acetylsalicylic acid	CHEBI:15365	acetylsalicylic acid		"{""preferred_term"": ""acetylsalicylic acid"", ""term"": {""id"": ""CHEBI:15365"", ""label"": ""acetylsalicylic acid""}}"
419	4233	4687	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	0	Pembrolizumab Plus Lenvatinib	Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"
426	4274	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
427	4274	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			pemetrexed	CHEBI:63616	pemetrexed		"{""preferred_term"": ""pemetrexed"", ""term"": {""id"": ""CHEBI:63616"", ""label"": ""pemetrexed""}}"
432	4299	4772	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	0	Ibrutinib	First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ibrutinib	CHEBI:76612	ibrutinib		"{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}"
433	4301	4773	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			acalabrutinib	CHEBI:167707	acalabrutinib		"{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}"
434	4306	4777	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	5	Venetoclax	BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"
444	4453	4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	treatment_term	surgical repair	MAXO:0009072	surgical repair	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	excision	NCIT:C15232	Excision		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}"
445	4456	4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	treatment_term	surgical repair	MAXO:0009072	surgical repair	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	shunt device	NCIT:C50174	Shunt Device		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""shunt device"", ""term"": {""id"": ""NCIT:C50174"", ""label"": ""Shunt Device""}}}"
446	4459	4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	treatment_term	surgical repair	MAXO:0009072	surgical repair	qualifier	0	treatment_term.qualifiers[0]	surgical procedure	NCIT:C15329	Surgical Procedure	excision	NCIT:C15232	Excision		"{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}"
447	4462	4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	treatment_term	gene therapy	MAXO:0001001	gene therapy	qualifier	0	treatment_term.qualifiers[0]	has participant	RO:0000057	has participant	CC2D2A	hgnc:29253	CC2D2A		"{""predicate"": {""preferred_term"": ""has participant"", ""term"": {""id"": ""RO:0000057"", ""label"": ""has participant""}}, ""value"": {""preferred_term"": ""CC2D2A"", ""term"": {""id"": ""hgnc:29253"", ""label"": ""CC2D2A""}}}"
451	4480	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			vandetanib	CHEBI:49960	vandetanib		"{""preferred_term"": ""vandetanib"", ""term"": {""id"": ""CHEBI:49960"", ""label"": ""vandetanib""}}"
452	4480	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			cabozantinib	CHEBI:72317	cabozantinib		"{""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}"
461	4558	5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	treatment_term	corticosteroid injection	MAXO:0000640	corticosteroid agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	triamcinolone	NCIT:C901	Triamcinolone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}"
462	4562	5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	infliximab	NCIT:C1789	Infliximab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}"
463	4565	5039	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	3	Anti-IL-12/23 therapy (ustekinumab)	"Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
"	treatment_term	immunosuppressive therapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent class	NCIT:C20401	Monoclonal Antibody					"{""predicate"": {""preferred_term"": ""therapeutic agent class"", ""term"": {""id"": ""NCIT:C20401"", ""label"": ""Monoclonal Antibody""}}}"
472	4708	5210	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	1	RET Kinase Inhibitors	Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			selpercatinib	CHEBI:175074	selpercatinib		"{""preferred_term"": ""selpercatinib"", ""term"": {""id"": ""CHEBI:175074"", ""label"": ""selpercatinib""}}"
476	4868	5372	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	1	Venetoclax plus Azacitidine	For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"
484	4892	5402	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	1	Entrectinib	TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			entrectinib	CHEBI:195558	entrectinib		"{""preferred_term"": ""entrectinib"", ""term"": {""id"": ""CHEBI:195558"", ""label"": ""entrectinib""}}"
489	4927	5449	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	1	Concurrent Chemoradiation	Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone.	treatment_term	radiation therapy	MAXO:0000014	radiation therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
490	4929	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			gemcitabine	CHEBI:175901	gemcitabine		"{""preferred_term"": ""gemcitabine"", ""term"": {""id"": ""CHEBI:175901"", ""label"": ""gemcitabine""}}"
491	4929	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
495	4981	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"
496	4981	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"
497	4981	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"
512	5412	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	triamcinolone	NCIT:C901	Triamcinolone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}"
513	5412	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	prednisone	NCIT:C770	Prednisone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""prednisone"", ""term"": {""id"": ""NCIT:C770"", ""label"": ""Prednisone""}}}"
514	5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	methotrexate	NCIT:C642	Methotrexate		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""methotrexate"", ""term"": {""id"": ""NCIT:C642"", ""label"": ""Methotrexate""}}}"
515	5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	mycophenolate mofetil	NCIT:C1468	Mycophenolate Mofetil		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""NCIT:C1468"", ""label"": ""Mycophenolate Mofetil""}}}"
516	5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	2	treatment_term.qualifiers[2]	therapeutic agent	NCIT:C2259	Therapeutic Agent	azathioprine	NCIT:C290	Azathioprine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}"
517	5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	3	treatment_term.qualifiers[3]	therapeutic agent	NCIT:C2259	Therapeutic Agent	cyclosporine	NCIT:C406	Cyclosporine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""cyclosporine"", ""term"": {""id"": ""NCIT:C406"", ""label"": ""Cyclosporine""}}}"
518	5426	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	adalimumab	NCIT:C65216	Adalimumab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adalimumab"", ""term"": {""id"": ""NCIT:C65216"", ""label"": ""Adalimumab""}}}"
519	5426	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	infliximab	NCIT:C1789	Infliximab		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}"
525	5576	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			dasatinib	CHEBI:49375	dasatinib		"{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}"
526	5576	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"
527	5579	6105	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	1	Ponatinib	Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ponatinib	CHEBI:78543	ponatinib		"{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}"
538	5717	6282	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	2	Hydroxyurea	First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"
539	5719	6283	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	3	Ruxolitinib	JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ruxolitinib	CHEBI:66919	ruxolitinib		"{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}"
544	5821	6404	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	0	Ruxolitinib	JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ruxolitinib	CHEBI:66919	ruxolitinib		"{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}"
545	5825	6407	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	3	Hydroxyurea	Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"
546	5827	6408	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	4	Anagrelide	Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			anagrelide	CHEBI:142290	anagrelide		"{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}"
553	5924	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	miransertib	NCIT:C99172	Miransertib		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""miransertib"", ""term"": {""id"": ""NCIT:C99172"", ""label"": ""Miransertib""}}}"
559	6004	6614	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	4	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"
575	6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			carboplatin	CHEBI:31355	carboplatin		"{""preferred_term"": ""carboplatin"", ""term"": {""id"": ""CHEBI:31355"", ""label"": ""carboplatin""}}"
576	6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			vincristine	CHEBI:27375	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}"
577	6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"
578	6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	3	treatment_term.therapeutic_agent[3]	therapeutic_agent			melphalan	CHEBI:28876	melphalan		"{""preferred_term"": ""melphalan"", ""term"": {""id"": ""CHEBI:28876"", ""label"": ""melphalan""}}"
587	6188	6842	292	SADDAN	SADDAN.yaml	treatments	0	Growth hormone therapy	Growth hormone therapy for marked short stature in SADDAN.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			growth hormone	CHEBI:37845	growth hormone		"{""preferred_term"": ""growth hormone"", ""term"": {""id"": ""CHEBI:37845"", ""label"": ""growth hormone""}}"
599	6370	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	treatment_term	coenzyme Q10 supplementation	MAXO:0010012	coenzyme Q10 supplementation	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	coenzyme Q10	NCIT:C916	Coenzyme Q10		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""coenzyme Q10"", ""term"": {""id"": ""NCIT:C916"", ""label"": ""Coenzyme Q10""}}}"
600	6373	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	treatment_term	carnitine supplementation	MAXO:0010006	carnitine supplementation	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	levocarnitine	NCIT:C26657	Levocarnitine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levocarnitine"", ""term"": {""id"": ""NCIT:C26657"", ""label"": ""Levocarnitine""}}}"
601	6376	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term	B vitamin supplementation	MAXO:0000761	B vitamin supplementation	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	thiamine	NCIT:C874	Thiamine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""thiamine"", ""term"": {""id"": ""NCIT:C874"", ""label"": ""Thiamine""}}}"
602	6376	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term	B vitamin supplementation	MAXO:0000761	B vitamin supplementation	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	riboflavin	NCIT:C808	Riboflavin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""riboflavin"", ""term"": {""id"": ""NCIT:C808"", ""label"": ""Riboflavin""}}}"
603	6381	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	treatment_term	ACE inhibitor therapy	MAXO:0000652	ACE inhibitor therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	captopril	NCIT:C340	Captopril		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""captopril"", ""term"": {""id"": ""NCIT:C340"", ""label"": ""Captopril""}}}"
604	6385	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term	diuretic agent therapy	MAXO:0000165	diuretic agent therapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	furosemide	NCIT:C515	Furosemide		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""furosemide"", ""term"": {""id"": ""NCIT:C515"", ""label"": ""Furosemide""}}}"
605	6385	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term	diuretic agent therapy	MAXO:0000165	diuretic agent therapy	qualifier	1	treatment_term.qualifiers[1]	therapeutic agent	NCIT:C2259	Therapeutic Agent	spironolactone	NCIT:C840	Spironolactone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}"
606	6390	7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	Levosimendan infusion	Levosimendan infusions used for heart failure support.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	levosimendan	NCIT:C174653	Levosimendan		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levosimendan"", ""term"": {""id"": ""NCIT:C174653"", ""label"": ""Levosimendan""}}}"
620	6605	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"
621	6605	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
628	6824	7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	loperamide hydrochloride	NCIT:C62046	Loperamide Hydrochloride		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""loperamide hydrochloride"", ""term"": {""id"": ""NCIT:C62046"", ""label"": ""Loperamide Hydrochloride""}}}"
629	6827	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	ciprofloxacin	NCIT:C376	Ciprofloxacin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""ciprofloxacin"", ""term"": {""id"": ""NCIT:C376"", ""label"": ""Ciprofloxacin""}}}"
630	6830	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	rifaximin	NCIT:C95262	rifaximin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}"
631	6833	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	bismuth subsalicylate	NCIT:C333	Bismuth Subsalicylate		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bismuth subsalicylate"", ""term"": {""id"": ""NCIT:C333"", ""label"": ""Bismuth Subsalicylate""}}}"
632	6838	7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	rifaximin	NCIT:C95262	rifaximin		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}"
654	7107	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"
655	7107	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	1	treatment_term.therapeutic_agent[1]	therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"
656	7107	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term	chemotherapy	MAXO:0000647	chemotherapy	therapeutic_agent	2	treatment_term.therapeutic_agent[2]	therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"
657	7147	7902	342	Wilson Disease	Wilsons_Disease.yaml	treatments	2	Zinc Acetate	Blocks intestinal copper absorption, maintenance therapy.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			zinc acetate	CHEBI:62984	zinc acetate		"{""preferred_term"": ""zinc acetate"", ""term"": {""id"": ""CHEBI:62984"", ""label"": ""zinc acetate""}}"
658	7150	7904	342	Wilson Disease	Wilsons_Disease.yaml	treatments	4	Tetrathiomolybdate	Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper.	treatment_term	copper chelator agent therapy	MAXO:0001224	copper chelator agent therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			tetrathiomolybdate	CHEBI:30703	tetrathiomolybdate(2-)		"{""preferred_term"": ""tetrathiomolybdate"", ""term"": {""id"": ""CHEBI:30703"", ""label"": ""tetrathiomolybdate(2-)""}}"
659	7167	7924	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	0	Nonsteroidal anti-inflammatory drugs	NSAIDs can reduce fever and inflammatory symptoms.	treatment_term	NSAID therapy	MAXO:0000221	NSAID therapy	therapeutic_agent	0	treatment_term.therapeutic_agent[0]	therapeutic_agent			naproxen	NCIT:C680	Naproxen		"{""preferred_term"": ""naproxen"", ""term"": {""id"": ""NCIT:C680"", ""label"": ""Naproxen""}}"
660	7170	7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	dapsone	NCIT:C415	Dapsone		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dapsone"", ""term"": {""id"": ""NCIT:C415"", ""label"": ""Dapsone""}}}"
661	7173	7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	treatment_term	pharmacotherapy	MAXO:0000058	pharmacotherapy	qualifier	0	treatment_term.qualifiers[0]	therapeutic agent	NCIT:C2259	Therapeutic Agent	azathioprine	NCIT:C290	Azathioprine		"{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}"
